Biomarker Type: Proteomic
-
Detection of Primary Immunotherapy Resistance to PD-1 Checkpoint Inhibitors in 2nd Line NSCLC
-
Combined plasma cfDNA mutations and a serum proteomic signature may identify non-responders to anti PD-1 treatment in NSCLC
-
Assessment of Plasma Proteomics Biomarker’s Ability to Distinguish Benign From Malignant Lung Nodules: Results of the PANOPTIC (Pulmonary Nodule Plasma Proteomic Classifier) Trial
-
Mass Spectrometry-based serum proteomic signature as a potential biomarker for survival in patients with non-small cell lung cancer receiving immunotherapy
-
Retrospective Assessment of a Serum Proteomic Test in a Phase III Study Comparing Erlotinib plus Tivantinib (MARQUEE) in Previously Treated Patients with Advanced Non-Small Cell Lung Cancer
-
Early Diagnosis of Pulmonary Nodules: Relative Contributions by Clinical Factors, Imaging, and Proteomics to a Clinical Biomarker
-
Early Diagnosis of Pulmonary Nodules: The Potential Effect of Observed Lymph Nodes on Performance of a Proteomic Biomarker
-
Pulmonary Nodule Biomarker PANOPTIC study results at 1-year supported by 2-year results
-
Erlotinib Plus Either Pazopanib or Placebo in Patients With Previously Treated Advanced Non-Small Cell Lung Cancer: A Randomized, Placebo-Controlled Phase 2 Trial With Correlated Serum Proteomic Signatures
-
Precision Medicine: Estimated Clinical and Economic Outcomes of Using a Predictive and Prognostic Biomarker to Avoid Ineffective Therapies in Advanced Non-Small Cell Lung Cancer